Tecaginlimab (Synonyms: BNT-312; DuoBody-CD40x-4-1BB; GEN1042)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Tecaginlimab  (Synonyms: BNT-312; DuoBody-CD40x-4-1BB; GEN1042) 纯度: 99.00%

Tecaginlimab (BNT-312) 是一种 Fc 惰性双特异性抗体，用于 CD40 和 4-1BB 的双重靶向和条件刺激。Tecaginlimab 可以增强肿瘤特异性免疫的启动和再激活。

  • Tecaginlimab (Synonyms: BNT-312; DuoBody-CD40x-4-1BB; GEN1042)
  • Tecaginlimab (Synonyms: BNT-312; DuoBody-CD40x-4-1BB; GEN1042)

  1. Tecaginlimab (Synonyms: BNT-312; DuoBody-CD40x-4-1BB; GEN1042)
  2. Tecaginlimab (Synonyms: BNT-312; DuoBody-CD40x-4-1BB; GEN1042)

CAS No. : 2253891-70-0

规格 价格 是否有货 数量
1 mg ￥5000 In-stock
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Tecaginlimab 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity[1].

同型

Human IgG1 kappa
推荐同型对照抗体

Human IgG1 kappa, Isotype Control
种属

Bispecific; Humanized

IC50 & Target[1]

CD40

 

4-1BB

 

体外研究
(In Vitro)

Tecaginlimab 结合重组人 CD40 和 4-1BB，亲和力分别为 1.0 nM 和 0.17 nM[1]。
Tecaginlimab (0.001-1 µg/mL; 5 d) 在体外诱导树突状细胞 (DC) 成熟[1]。
Tecaginlimab (0.2 µg/mL; 10-15 d) 在体外增强 T 细胞活化[1]。

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Tecaginlimab 相关抗体:
体内研究
(In Vivo)

Tecaginlimab (0.0008-0.2 µg/mL; 4 d) 增强肿瘤浸润淋巴细胞的扩增[1]。

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

CAS 号

2253891-70-0
性状

液体

颜色

Colorless to light yellow

运输条件

Shipping with dry ice.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Tecaginlimab (Synonyms: BNT-312; DuoBody-CD40x-4-1BB; GEN1042)
    Human IgG1 kappa
纯度 & 产品资料

纯度: 99.00%

Data Sheet (518 KB) SDS (251 KB)

COA (172 KB)

抗体抑制剂使用指南 (1152 KB)

参考文献

  • [1]. Muik A, et, al. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity. J Immunother Cancer. 2022 Jun;10(6):e004322.  [Content Brief]

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务